Related references
Note: Only part of the references are listed.Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms
Emmanuele Crespan et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells
Ruriko Tanaka et al.
BLOOD (2010)
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants
Ellen Weisberg et al.
BLOOD (2010)
Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo
S. A. Bright et al.
BRITISH JOURNAL OF CANCER (2010)
AP24163 Inhibits the Gatekeeper Mutant of BCR-ABL and Suppresses In vitro Resistance
Mohammad Azam et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2010)
Novel dual Src/Abl inhibitors for hematologic and solid malignancies
Silvia Schenone et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib
Michael Koldehoff et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant
Wei-Sheng Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors
Jianming Zhang et al.
NATURE (2010)
The Antiproliferation Effect of Berbamine on K562 Resistant Cells by Inhibiting NF-κB Pathway
Yan-Lin Wei et al.
ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY (2009)
Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities
Konstantin J. Dedes et al.
ANTI-CANCER DRUGS (2009)
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation
Yukimasa Shiotsu et al.
BLOOD (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Peter Atadja
CANCER LETTERS (2009)
Sorafenib Induces Apoptosis Specifically in Cells Expressing BCR/ABL by Inhibiting Its Kinase Activity to Activate the Intrinsic Mitochondrial Pathway
Tetsuya Kurosu et al.
CANCER RESEARCH (2009)
A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies
Christine M. Hartford et al.
CLINICAL CANCER RESEARCH (2009)
Clinical Studies of Histone Deacetylase Inhibitors
H. Miles Prince et al.
CLINICAL CANCER RESEARCH (2009)
Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent
Britt Erika Hanson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells
Cristian Bellodi et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance
Wenyong W. Zhang et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Discovery of Novel 2-Aminobenzamide Inhibitors of Heat Shock Protein 90 as Potent, Selective and Orally Active Antitumor Agents
Kenneth H. Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor
Chikara Hirase et al.
LEUKEMIA RESEARCH (2009)
Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?
Elias Jabbour et al.
MAYO CLINIC PROCEEDINGS (2009)
ERK2, but Not ERK1, Mediates Acquired and De novo Resistance to Imatinib Mesylate: Implication for CML Therapy
Clara I. Aceves-Luquero et al.
PLOS ONE (2009)
Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy
Timothy P. Hughes et al.
BLOOD (2008)
HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells
Rekha Rao et al.
BLOOD (2008)
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I
Artur Gontarewicz et al.
BLOOD (2008)
Resveratrol induces apoptosis in K562 (chronic myelogenous leukemia) cells by targeting a key survival protein, heat shock protein 70
Prabir K. Chakraborty et al.
CANCER SCIENCE (2008)
Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL:: In vitro and in vivo studies
Daigo Akahane et al.
CANCER SCIENCE (2008)
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia
Alfonso Quintas-Cardama et al.
CLINICAL CANCER RESEARCH (2008)
The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications
Amancio Carnero et al.
CURRENT CANCER DRUG TARGETS (2008)
Inhibitors of ABL and the ABL-T315I mutation
Glenn Noronha et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2008)
Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol
Alexandre Puissant et al.
FASEB JOURNAL (2008)
Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy
Ju-Huei Chien et al.
LEUKEMIA RESEARCH (2008)
SGX393 inhibits the CML mutant Bcr-AblT3151 and preempts in vitro resistance when combined with nilotinib or dasatinib
Thomas O'Hare et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070
S. Dong et al.
LEUKEMIA (2008)
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors
Mhairi Copland et al.
BLOOD (2008)
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment
Andreas Hochhaus et al.
BLOOD (2008)
Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia
C. Sillaber et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2008)
Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics
Jami McLaughlin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
Jorge Cortes et al.
CANCER (2007)
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib
Jorge Cortes et al.
CANCER (2007)
Crystal structure of the T315l Abl mutant in complex with the aurora kinases inhibitor PHA-739358
Michele Modugno et al.
CANCER RESEARCH (2007)
Modulating autophagy for therapeutic benefit
Jennifer S. Carew et al.
AUTOPHAGY (2007)
被撤回的出版物: Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve mcl-1 and p21CIP1 down-regulation(Retracted article. See vol.22, pg.4959,2016)
Girija Dasmahapatra et al.
CLINICAL CANCER RESEARCH (2007)
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance
Jennifer S. Carew et al.
BLOOD (2007)
Structural basis for potent inhibition of the Aurora kinases and a T3151 multi-drug resistant mutant form of Abl kinase by VX-680
G. M. T. Cheetham et al.
CANCER LETTERS (2007)
Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis
Seiichi Okabe et al.
STEM CELLS AND DEVELOPMENT (2007)
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825
Tri K. Nguyen et al.
BLOOD (2007)
Ras as a therapeutic target in hematologic malignancies
Yesid Alvarado et al.
EXPERT OPINION ON EMERGING DRUGS (2007)
Degrasyn activates proteasomal-dependent degradation of c-Myc
Geoffrey Bartholomeusz et al.
CANCER RESEARCH (2007)
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells
Geoffrey A. Bartholomeusz et al.
BLOOD (2007)
Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity
Son B. Le et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Adaphostin cytoxicity in glioblastoma cells is ROS-dependent and is accompanied by upregulation of heme oxygenase-1
Jason Long et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
Francis J. Giles et al.
BLOOD (2007)
The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant Bcr/Abl(+) human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation
Mohamed Rahmani et al.
MOLECULAR PHARMACOLOGY (2007)
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia
Simona Soverini et al.
CLINICAL CANCER RESEARCH (2006)
1,4,5,6-tetrahydropyrrolo[3,4-c] pyrazoles:: Identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile
Daniele Fancelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Comparison of imatinib, mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen:: high efficacy of drug combinations
Heather A. Bradeen et al.
BLOOD (2006)
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E. Jabbour et al.
LEUKEMIA (2006)
Cotreatment with vorinostat (Suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells
Warren Fiskus et al.
CLINICAL CANCER RESEARCH (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells
Warren Fiskus et al.
BLOOD (2006)
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance
Mohammad Azam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl
M Li et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate
TK Nguyen et al.
CLINICAL CANCER RESEARCH (2006)
Allosteric inhibitors of Bcr-abl-dependent cell proliferation
FJ Adrián et al.
NATURE CHEMICAL BIOLOGY (2006)
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy
G Borthakur et al.
CANCER (2006)
Berbamine: A novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity
RZ Xu et al.
LEUKEMIA RESEARCH (2006)
Abrogation of heat shock protein 70 induction as a strategy, to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
F Guo et al.
CANCER RESEARCH (2005)
BIRB-796 is not an effective ABL(T315I) inhibitor
T O'Hare et al.
NATURE BIOTECHNOLOGY (2005)
BIRB-796 is not an effective ABL(T315I) inhibitor - Response
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
A Burchert et al.
LEUKEMIA (2005)
被撤回的出版物: Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL plus human leukemia cells (Retracted article. See vol. 30, pg. 1452, 2016)
C Yu et al.
LEUKEMIA (2005)
T315l-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study
S Pricl et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
P Bali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro
HG Jorgensen et al.
LEUKEMIA (2005)
Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance
PH Tseng et al.
BLOOD (2005)
Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells
JME Withey et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and bax conformational change
M Rahmani et al.
MOLECULAR PHARMACOLOGY (2005)
Drug Insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid
WK Kelly et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
P George et al.
BLOOD (2005)
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance
K Gumireddy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate
T Illmer et al.
LEUKEMIA (2004)
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
NJ Donato et al.
CANCER RESEARCH (2004)
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2
Y Dai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Aurora kinases in spindle assembly and chromosome segregation
D Ducat et al.
EXPERIMENTAL CELL RESEARCH (2004)
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML
T O'Hare et al.
BLOOD (2004)
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib
HK Al-Ali et al.
HEMATOLOGY JOURNAL (2004)
Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia
M Mayerhofer et al.
CANCER RESEARCH (2004)
Phosphatidylinositol-3 kinase inhibitors reproduce the selective anti proliferative effects of imatinib on chronic myeloid leukaemia progenitor cells
SB Marley et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells
J Chandra et al.
BLOOD (2003)
Kinase components of the Ras-MAPK signaling cascade as potential targets for therapeutic intervention
DM Berger et al.
DRUGS OF THE FUTURE (2003)
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571
CR Yu et al.
BLOOD (2003)
Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways
CR Yu et al.
CANCER BIOLOGY & THERAPY (2003)
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
S Branford et al.
BLOOD (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies
J Cortes et al.
BLOOD (2003)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin
M Mayerhofer et al.
BLOOD (2002)
Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy
A Hochhaus et al.
LEUKEMIA (2002)
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90
ME Gorre et al.
BLOOD (2002)
Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids
V Rapozzi et al.
NUCLEIC ACIDS RESEARCH (2002)
Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571
A Klejman et al.
ONCOGENE (2002)
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336
RR Hoover et al.
BLOOD (2002)
Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate
J Regan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
S Branford et al.
BLOOD (2002)
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571:: a prospective study
N von Bubnoff et al.
LANCET (2002)
Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro
BMF Mow et al.
BLOOD (2002)
Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats
MJ Egorin et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation
WK Hofmann et al.
BLOOD (2002)
The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy
MV Blagosklonny et al.
LEUKEMIA (2001)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
JE Karp et al.
BLOOD (2001)
Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336
A Reichert et al.
BLOOD (2001)
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
DG Peters et al.
BLOOD (2001)
Farnesylated proteins and cell cycle progression
F Tamanoi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2001)
Discovery of (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity
JT Hunt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
